Skip to main content
TipRanks
Go Ultimate75% OFF

Novavax (NVAX) Stock Price & Analysis

10,193 Followers

NVAX Stock Chart & Stats

$7.47-$0.25(-3.24%)
At close: 4:00 PM EST
$7.5$10$12.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$7.43 - $7.98
52-Week Range
$6.25 - $13.39
Previous Close
$7.72
Volume
N/A
Average Volume (3M)
6.29M
Market Cap
$1.23B
Enterprise Value
$1.46B
Total Cash (Recent Filing)
$622.36M
Total Debt (Recent Filing)
$295.26M
Price to Earnings (P/E)
―
Beta
1.50
Next Earnings
Mar 04, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Sanofi Partnership Monetization

The Sanofi alliance has demonstrated substantial commercial value through more than $1 billion of cumulative revenue and a new $125 million milestone. Further technology-transfer, launch, and royalty opportunities could provide durable non-product revenue and validate Novavax’s platform.

Cash Runway And Operating Discipline

A multiyear cash runway gives Novavax time to advance its portfolio and absorb uneven vaccine demand without immediate financing pressure. Planned reductions in R&D, SG&A, headcount, and facilities should also improve operating leverage as partner support work winds down.

Validated Matrix-M Platform

Use of Matrix-M in two commercial vaccines provides real-world validation beyond a single COVID product and expands potential applications across infectious disease. Broad partner interest may create additional licensing, supply, and collaboration opportunities over time.

Bears Say

Volatile And Declining Revenue

The sharp reversal from strong annual results to lower TTM revenue shows that Novavax’s earnings base remains highly dependent on changing vaccine demand and contract timing. Negative operating margins indicate current revenue is not yet sufficient to support the cost structure sustainably.

Persistently Negative Shareholders’ Equity

A negative equity position reduces balance-sheet resilience and makes leverage measures less favorable, even when absolute debt is moderate. This limits financial flexibility during weak operating periods and increases dependence on successful milestones, partnerships, or future external funding.

Ongoing Cash Burn

Persistent operating and free-cash-flow losses mean Novavax is consuming liquidity rather than internally funding its business. Even with stated runway, continued burn raises execution pressure and makes future investment capacity more dependent on milestones, product sales, and cost reductions.

Novavax News

NVAX FAQ

What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $6.25 and its highest was $13.39 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.23B.
When is Novavax’s upcoming earnings report date?
Novavax’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 102 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Nov 05, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.346 by $0.156.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is 0.54.
How many shares outstanding does Novavax have?
Novavax has 165,009,000 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.346. Following the earnings report the stock price went down -8.169%.
Which hedge fund is a major shareholder of Novavax?
Hedge funds hold Novavax shares: the largest hedge-fund position in Novavax is 72,325,942 shares, and hedge funds increased their holdings by 1.8M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology